Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Share price taken down
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1)
•••
Comment by CalgaryATEon May 17, 2021 11:44am
258 Views
Post# 33214130

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Share price taken down

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Share price taken downIf you go to around the 22/23 minute mark of the Radius Research interview (Apr. 19, 2021)

https://www.youtube.com/watch?v=AUOUcUAbzG0

Dan talks about 352, I believe he said about 12-15 months to start phase 1 (so April, May, June or July 2022 start date).


WalkOverTheStrt wrote: Mugs - any indication that mgmt tries to accelerate 352  "Currently in IND-enabling studies — human trials slated for 2022"?  It just seems like a very open date and having watched Dan and team push timelines out Im curious if with the funding they will try to make up for lost time. IMO and I'm a broken record until Antibe has more than one human drug results (positive) this HS2 molecule is not a platform. It's a potential.... 
A PH1 trial could be completed in a year with results... My concern is Dan and team do not start 352 in early 2022 and instead keep kicking it down the road. 
Has Dan indicated this could be pulled in? 


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities